Yohann Loriot
1,439 works · 57,538 citations · h-index 83
Top works
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- Prevalence and causes of burnout amongst oncology residents: A comprehensive nationwide cross-sectional study